Graves’ Disease in Pregnancy: A Systematic Review
Introduction: Graves’ disease is an autoimmune disease that is associated with thyroid gland involvement and is most common in young women. During pregnancy, it is the main cause of hyperthyroidism, as the thyroid gland volume and thyroid hormone synthesis increase. Changes in the immune system during pregnancy can affect the onset of disease. During pregnancy, the pathological cause of Graves’ disease is immune deficiency. This study investigated changes in the thyroid gland occurring during pregnancy, the causes of Graves’ disease during pregnancy, and its diagnosis and treatment.
Methods: A search of Google scholar, Ovid, and MEDLINE was conducted with the search terms Graves’ disease, pregnancy, and treatment.
Results: A total of 65 titles were initially identified with the search strategy described. Twenty-five publications were excluded. Out of the remaining articles, 19 articles were used in terms of content. Treatment for Graves’ disease is determined according to the patient’s condition, the priority of the patient, and the resources available. Treatments include oral anti-thyroid drugs (ATDs), radioactive iodine, and surgical procedures. Among the oral prophylactic drugs, Propylthiouracil is used during lactation. Radioactive iodine is not used during pregnancy or lactation. Thyroidectomy is better to be used in the third trimester of pregnancy.
Conclusion: The treatment of Graves’ disease is very important; if not treated, this disease causes many complications with the fetus. After delivery, the mother and the baby should be monitored for thyroid problems. Pre- and postpartum planning and the effective management of Graves’ disease in women of childbearing age are necessary to prevent the pathogenesis of Graves’ disease during pregnancy.
Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease. Autoimmun Rev. 2014;13(4-5):398-402. doi:10.1016/j.autrev.2014.01.013.
Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med. 2016;375(16):1552-1565. doi:10.1056/NEJMra1510030.
McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252-265. doi:10.1007/s12020-012-9703-2.
Orgiazzi J. pregnancy modulates the incidence of Graves’ hyperthyroidism. Clin Thyroidol. 2015;27(1):20-22. doi:10.1089/ct.2015;27.20-22.
Hemminki K, Li X, Sundquist J, Sundquist K. The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution. J Autoimmun. 2010;34(3):J307-313. doi:10.1016/j.jaut.2009.11.019.
Mestman JH. The incidence of Graves’ hyperthyroidism increases in early pregnancy and the late postpartum period. Clin Thyroidol. 2015;27(5):112-114. doi:10.1089/ct.2015;27.112-114.
Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt). 2009;18(11):1847-1856. doi:10.1089/jwh.2008.1234.
LaFranchi S. Thyroid hormone in hypopituitarism, Graves’ disease, congenital hypothyroidism, and maternal thyroid disease during pregnancy. Growth Horm IGF Res. 2006;16 Suppl A:S20-S24. doi:10.1016/j.ghir.2006.03.015.
Laurberg P, Andersen SL. ENDOCRINOLOGY IN PREGNANCY: Pregnancy and the incidence, diagnosing and therapy of Graves’ disease. Eur J Endocrinol. 2016;175(5):R219-R230. doi:10.1530/EJE-16-0410.
Casey BM, Leveno KJ. Thyroid disease in pregnancy. Obstet Gynecol. 2006;108(5):1283-1292. doi:10.1097/01.AOG.0000244103.91597.c5.
Chattaway JM, Klepser TB. Propylthiouracil versus methimazole in treatment of Graves’ disease during pregnancy. Ann Pharmacother. 2007;41(6):1018-1022. doi:10.1345/aph.1H535.
Papendieck P, Chiesa A, Prieto L, Gruneiro-Papendieck L. Thyroid disorders of neonates born to mothers with Graves’ disease. J Pediatr Endocrinol Metab. 2009;22(6):547-553. doi:10.1515/JPEM.2009.22.6.547.
Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with hyperthyroidism: a cohort study. Arch Gynecol Obstet. 2011;283(2):243-247. doi:10.1007/s00404-010-1362-z.
Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab. 2007;3(6):470-478. doi:10.1038/ncpendmet0508.
Elston MS, Tu’akoi K, Meyer-Rochow GY, Tamatea JAU, Conaglen JV. Pregnancy after definitive treatment for Graves’ disease – Does treatment choice influence outcome? Aust N Z J Obstet Gynaecol. 2014;54(4):317-321. doi:10.1111/ajo.12196.
Okosieme OE, Lazarus JH. Important considerations in the management of Graves’ disease in pregnant women. Expert Rev Clin Immunol. 2015;11(8):947-957. doi:10.1586/1744666X.2015.1054375.
Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol. 2013;20(2):660-667. doi:10.1245/s10434-012-2606-x.
Rotondi M, Cappelli C, Pirali B, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93(10):3985-3988. doi:10.1210/jc.2008-0966.
Levy-Shraga Y, Tamir-Hostovsky L, Boyko V, Lerner-Geva L, Pinhas- Hamiel O. Follow-up of newborns of mothers with Graves’ disease. Thyroid. 2014;24(6):1032-1039. doi:10.1089/thy.2013.0489.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Medical Reviews is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.